UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 10, 2016 (August 4, 2016)
IMPLANT SCIENCES CORPORATION
(Exact name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)
001-14949 |
| 04-2837126 |
(Commission File Number) |
| (I.R.S. Employer Identification Number) |
500 Research Drive, Unit 3
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices, including Zip Code)
(978) 752-1700
(Registrant’s Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01
Regulation FD Disclosure
On August 3, 2016, the Company issued the press release announcing a conference call to provide additional information on the Company’s proposed acquisition of Zapata Industries SAS. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 8.01 Other Events
On August 4, 2016, the Company held a telephonic conference call to provide additional information on the Company’s proposed acquisition of Zapata Industries SAS. A copy of the transcript of the conference call is attached hereto as Exhibit 99.2 and is incorporated herein by this reference.
The press release and the Company’s conference call script furnished under Item 7.01 and 8.01, including Exhibits 99.1 and 99.2, of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
|
Exhibit No. | Description |
99.1 | Press Release of Implant Sciences Corporation, dated August 3, 2016, to announce the conference call. |
99.2 | Implant Sciences Corporation conference call transcript held on August 4, 2016 at 4:15 PM ET. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMPLANT SCIENCES CORPORATION
By: /s/ Roger P. Deschenes
Name: Roger P. Deschenes
Title: Vice President, Finance and Chief Financial Officer
Date: August 10, 2016
EXHIBIT INDEX
|
|
Exhibit No. | Description |
99.1 | Press Release of Implant Sciences Corporation, dated August 3, 2016, to announce the conference call. |
99.2 | Implant Sciences Corporation conference call transcript held on August 4, 2016 at 4:15 PM ET. |